Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.38 |
| ▸ | NPY1R | P25929 | 9/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.38 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27113590 | 0.92 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL27112906 | 0.90 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL23690778 | 0.88 | MEN1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL20221707 | 0.88 | MEN1 (0.40) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL26880961 | 0.86 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL4572264 | 0.86 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL14012343 | 0.86 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL27113592 | 0.85 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL13863591 | 0.85 | MEN1 (0.42) | NPY4RNPY1RNPY5RNPY2RMEN1 | |
| SCHEMBL23841195 | 0.85 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-8415277-B2 | Bi-functional compound positively charged at first pH and negatively charged at second pH, solid support comprising the bi-functional compound, and method of isolating nucleic acid using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | GLB1, LUC7L2, GUSB | NPY4R 4428/4885NPY1R 4568/4885NPY5R 2691/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | NPY4R 3178/4885NPY1R 3757/4885NPY5R 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.